Skip to main content
WorldVoice 360
BusinessUnited States

McKinsey Reaches $650 Million Settlement Over Opioid Crisis Role

Consulting firm acknowledges its involvement in the opioid epidemic linked to OxyContin misbranding.

Source: bbc.co.uk1 min read
McKinsey Reaches $650 Million Settlement Over Opioid Crisis Role
Image via bbc.co.uk

In brief

In a significant legal move, McKinsey & Company has consented to a $650 million settlement concerning its participation in the US opioid crisis through its association with Purdue Pharma.

The high-profile consulting firm McKinsey & Company has agreed to pay $650 million to settle criminal charges linked to its involvement in the US opioid crisis. According to the US Department of Justice, the company allegedly conspired with Purdue Pharma to “aid and abet the misbranding of prescription drugs... without valid prescriptions.” McKinsey has faced accusations of conspiring to misbrand drugs and obstructing justice by advising Purdue Pharma on strategies to enhance the sales of OxyContin, a widely-used painkiller. In response, McKinsey issued an apology, acknowledging that "we should have appreciated the harm opioids were causing in our society." In a related development, former McKinsey senior partner Martin Elling has reportedly agreed to plead guilty to obstruction for destroying evidence connected to the case. The US Department of Justice announced that McKinsey has entered into a deferred prosecution agreement, which will lapse in five years, contingent on the firm's compliance with stipulations laid out by the prosecutors.This settlement follows McKinsey's earlier agreement to pay nearly $1 billion in lawsuits connected to its dealings with Purdue Pharma and other pharmaceutical manufacturers. Purdue Pharma, notorious for its role in exacerbating the opioid crisis, pleaded guilty in 2020 and agreed to an $8.3 billion settlement for criminal charges linked to its promotion of OxyContin. This medication, launched in the mid-1990s, was identified as having 68% of the oxycodone market share by 2002, and the subsequent abuse of opioids has led to a dramatic rise in addiction and overdose cases in the United States.The opioid crisis has resulted in nearly 100,000 deaths each year due to drug overdoses across the U.S., with the latest data showing 97,000 overdose deaths from June 2023 to June 2024—a 14% decline compared to the previous year. As the nation confronts this pressing health crisis, experts express cautious optimism surrounding the trends in drug overdose fatalities.

Topics

More on this story